Do you treat patients with metastatic renal cell carcinoma who progress on first-line TKI with single agent nivolumab or the combination of nivolumab plus ipilimumab?

This is an interesting and timely question that clinicians will face. Although data for nivo monotherapy in the front line is sparse, it is clear to me that the combo has more activity than nivo monotherapy based on ORR and CR rate. It also carries more toxicity. One approach would be to start patie...